Healwell talks Darwen AI peer-reviewed publications

Executive Summary

• Healwell AI Inc. announced that its Darwen AI platform has reached 47 peer-reviewed publications, significantly strengthening its scientific validation and commercial moat for generating real-world clinical evidence.
• The company secured three additional conference acceptances for 2026 in collaboration with global life sciences partners, focusing on inflammatory bowel disease, Type 2 diabetes, and plaque psoriasis.
• New research demonstrates how AI-enriched patient data can generate real-world evidence for U.S. Medical Affairs and market access, driving new partnership inquiries and expanding commercial opportunities.

Key Details

• Total peer-reviewed publications validating the Darwen AI platform now stands at 47.
• New research accepted for presentation at the European Crohn's and Colitis Organisation (ECCO) meeting, with publication in the Journal of Crohn's and Colitis.
• Study conducted with the U.S. affiliate of a large pharmaceutical partner, showing AI-enriched Canadian patient support program data can generate real-world evidence for U.S. market access initiatives.
• Three additional conference acceptances secured for 2026 in collaboration with leading global life sciences companies.
• New clinical research studies examine: treatment patterns for inflammatory bowel disease; AI-enabled clinical decision support for Type 2 diabetes quality standards; and suicidal ideation/behavior in plaque psoriasis patients receiving systemic therapies.
• Darwen AI transforms unstructured clinical data from electronic health records (EHRs) into structured, research-ready insights for healthcare systems and life sciences companies.
• Validation spans multiple therapeutic areas including cancer, cardiovascular disease, chronic disease, dermatology, gastrointestinal diseases, infectious diseases, mental health, ophthalmology, rare diseases, social determinants of health, and substance use.
• Platform has analyzed millions of clinical records while maintaining research-grade rigor across diverse patient populations and ethnicities.

Notable Quotes

• Sacha Gera, Chief Operating Officer: "The scientific team at Healwell continues to set the standard for clinically validated AI, producing peer-reviewed research that carries real weight in the global medical community. What is particularly exciting is seeing this work expand globally through collaborations with the U.S. affiliates of our existing pharmaceutical partners, extending the reach and impact of Darwen AI across new markets. Each publication generates new partnership inquiries, which generate new data access, which enables new publications, creating a compounding scientific and commercial moat that becomes harder to replicate with every study."
• James Lee, Chief Executive Officer: "We are building the scientific foundation that will make Darwen the default AI layer for real-world evidence generation in global health care. Scientific validation is a critical component of that strategy. Each new peer-reviewed publication strengthens the credibility of Darwen AI and expands its validation across additional disease areas and clinical settings. With 47 peer-reviewed publications and growing, we believe our clinically validated AI will play an increasingly important role in helping health care systems and researchers unlock insights from real-world data, improve clinical decision making and ultimately deliver better patient outcomes."